VP1-2023: Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study
- Resource Type
- Source
- Annals of Oncology. 34:319-320
- Subject
Oncology Hematology - Language
- ISSN
- 0923-7534